Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Shattuck Labs Inc (STTK)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$5.15-5.85%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for STTK yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
maintain sufficient cash through financing | The company maintains cash flow through recent $75M stock offering. | Intact | no successful capital raises of at least $75M within next 12 months | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk clinical-stage biotech with a sector tailwind and a thesis driven by development progress rather than current earnings. The long-term thesis remains under watch: key programs are on schedule, but recent financial performance is weak and the business is loss-making.
The valuation model has low confidence and shows STTK at a premium to peers, with optionality as the main reason for the gap. The evidence labels that premium unjustified, so the market appears to be assigning value to future development potential without strong support from current fundamentals.
Near term, management says the SL-325 Phase 2b trial remains on track, SL-846 development is on schedule, and available cash is expected to fund operations into 2029. Recent financial performance remains weak, the risk label has risen to high, and a guidance cut or weaker jobs data could add pressure to the business outlook.
Over the multi-year view, a key test is whether SL-325 advances through its planned trial, with primary endpoint data anticipated in the first half of 2028; SL-846's planned Phase 1 start in the first half of 2027 is another milestone. The near-term outlook also hinges on guidance and broader conditions: weaker jobs data could weigh on cyclical names, while stronger results from sector bellwethers could support Healthcare-sector momentum.
STTK has a funded clinical-development plan and sector support, but its loss-making position, weak recent performance, and peer valuation premium leave the 1-to-3-year thesis dependent on execution and trial progress. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Shattuck Labs Inc's published investment case. The stated target is EPS loss improves to less than -$0.40 per share next 12 months. |
| Broken |
| EPS loss worsens beyond -$0.50 per share next 12 months |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
sustain or improve revenue trajectory | A primary condition in Shattuck Labs Inc's published investment case. The stated target is revenue decline less than 10% next 12 months. | Broken | revenue decline exceeds 10% next 12 months | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.52 → $-0.52 · observed estimates
$0.02B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.52 | $19,300,000 | 6 / 6 |
| 2026-07-25 | $-0.52 | $19,300,000 | 6 / 6 |
| 2026-07-26 | $-0.50 | $19,300,000 | 6 / 6 |
| 2026-07-27 | $-0.50 | $19,300,000 | 6 / 6 |
| 2026-07-28 | $-0.50 | $19,300,000 | 6 / 6 |
| 2026-07-29 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-07-30 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-07-31 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-01 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-02 | $-0.50 | $0 | 9 / 8 |
| 2026-08-03 | $-0.50 | $0 | 9 / 8 |
| 2026-08-04 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-05 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-06 | $-0.50 | $0 | 9 / 8 |
| 2026-08-08 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-09 | $-0.50 | $0 | 9 / 8 |
| 2026-08-10 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-12 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-13 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-14 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-15 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-16 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-17 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-18 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-19 | $-0.50 | $19,300,000 | 7 / 8 |
| 2026-08-20 | $-0.52 | $19,300,000 | 7 / 8 |
| 2026-08-21 | $-0.52 | $19,300,000 | 7 / 8 |
| 2026-08-22 | $-0.52 | $19,300,000 | 7 / 8 |
| 2026-08-23 | $-0.52 | $19,300,000 | 7 / 8 |
| 2026-08-24 | $-0.52 | $19,300,000 | 7 / 8 |
| 2026-08-25 | $-0.53 | $110,000 | 7 / 8 |
| 2026-08-26 | $-0.53 | $110,000 | 7 / 9 |
| 2026-08-27 | $-0.53 | $110,000 | 7 / 9 |
| 2026-08-28 | $-0.53 | $110,250 | 8 / 6 |
| 2026-08-29 | $-0.53 | $110,250 | 8 / 6 |
| 2026-08-30 | $-0.53 | $110,250 | 8 / 6 |
| 2026-08-31 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-01 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-02 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-03 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-04 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-05 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-06 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-07 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-08 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-09 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-10 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-11 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-12 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-13 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-14 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-15 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-16 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-17 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-18 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-19 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-20 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-21 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-22 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-23 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-24 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-25 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-26 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-27 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-28 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-29 | $-0.53 | $110,250 | 8 / 6 |
| 2026-09-30 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-01 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-02 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-03 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-04 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-05 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-06 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-07 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-08 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-09 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-10 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-11 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-12 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-13 | $-0.53 | $110,250 | 8 / 6 |
| 2026-10-14 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-15 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-16 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-17 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-18 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-19 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-20 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-21 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-22 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-23 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-24 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-25 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-26 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-27 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-28 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-29 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-30 | $-0.52 | $100,227 | 9 / 6 |
| 2026-10-31 | $-0.52 | $100,227 | 9 / 6 |
| 2026-11-01 | $-0.52 | $100,227 | 9 / 6 |
| 2026-11-02 | $-0.52 | $100,227 | 9 / 6 |
| 2026-11-03 | $-0.52 | $100,227 | 9 / 6 |
| 2026-11-04 | $-0.52 | $100,227 | 9 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 12 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.